QT Imaging Holdings Inc Dossier - Source-backed chat

QT Imaging Holdings Inc

QTINASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.34

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.53Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $37M

Enterprise Value $37.5M

Shares Outstanding 15.5M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

QT Imaging Holdings, Inc. (NASDAQ: QTI) is transitioning from a traditional hardware-centric medical scanner manufacturer to a high-margin, scalable SaaS and biomarker-driven medical imaging platform. The company's proprietary Breast Acoustic CT™ technology offers a radiation-free, compression-free 3D alternative to traditional mammography, which is highly effective for dense breast tissue. While Q1 2026 revenue surged 133% year-over-year to $6.5 million driven by 13 scanner shipments, the company remains unprofitable with a net loss of $3.4 million. The recent $10 million public offering in May 2026 and the extension of its senior secured term loan maturity to 2029 provide near-term financial runway. However, persistent cash burn and dilution risks warrant a cautious Hold recommendation until the high-margin QTI Cloud SaaS platform demonstrates meaningful commercial traction.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$11.60

High · most bullish analyst$13.20

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Scanner shipments slow down due to supply chain or distribution bottlenecks, causing the company to miss its $39 million FY 2026 revenue target. High cash burn persists, requiring further dilutive equity raises. The adoption of the Category III CPT code is delayed or rejected by major insurance payers, limiting U.S. commercial adoption.

Base CaseCentral scenario

The company successfully delivers on its FY 2026 revenue guidance of approximately $39 million, supported by minimum order quantities (MOQs) from its U.S. distributor NXC Imaging and Gulf region partners (Gulf Medical and Al Naghi Medical). The initial rollout of the QTI Cloud SaaS platform begins to contribute high-margin recurring revenue, helping to stabilize gross margins. The newly secured Category III CPT code (effective January 2027) paves the way for broader U.S. clinical adoption and insurance reimbursement.

Bull CaseUpside scenario

QT Imaging is transitioning from a hardware-only scanner manufacturer to a high-margin SaaS and biomarker-driven medical imaging franchise. The bull case is supported by: (1) Strong commercial momentum with 2026 revenue guided at approximately $39 million (more than double 2025's $18.9 million), driven by contracted minimum order quantities (MOQs) with distribution partners like NXC Imaging (Canon Medical Systems USA subsidiary) and Gulf region partners. (2) Significant regulatory milestones, including official classification and clearance from the Saudi Food and Drug Authority (SFDA) in June 2026 and UAE clearance, opening up the largest Middle Eastern healthcare markets. (3) Technological expansion of its QTI Cloud Platform through a strategic collaboration with Olea Medical to integrate advanced visualization and AI-ready imaging technologies. (4) Progress toward U.S. reimbursement, having secured a dedicated Category III CPT code specific to its 3D breast acoustic CT technology, effective January 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary, FDA-cleared radiation-free and compression-free 3D breast imaging technology highly suited for dense breast tissue.
Strong revenue growth momentum, with FY 2025 revenue up 288% to $18.9 million and Q1 2026 revenue up 133% to $6.5 million.
Established multi-year international distribution agreements in the Gulf region representing over $24 million in committed scanner revenue.
Secured a dedicated Category III CPT code effective January 2027, establishing a clear path to U.S. clinical reimbursement.

Key Investment Risks

Ongoing operational unprofitability, with a net loss of $3.4 million in Q1 2026 and an accumulated deficit of $56.4 million.
High cash burn rate, with $3.7 million used in operating activities during Q1 2026, necessitating frequent capital raises.
Dilution risk for existing shareholders, highlighted by the $10 million underwritten public offering completed in May 2026.
Dependence on a limited number of strategic distribution partners (e.g., NXC Imaging, Al Naghi Medical, Gulf Medical) to meet minimum order quantities.

Thesis Invalidation Triggers

Failure to meet the FY 2026 revenue guidance of approximately $39 million.
Significant delays in the commercial launch or clinical adoption of the QTI Cloud SaaS platform.
Inability to secure favorable reimbursement coverage from major U.S. insurance payers under the new CPT code in 2027.
A severe liquidity crunch where cash reserves fall below operational requirements without access to non-dilutive financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.